Last reviewed · How we verify

Lorlatinib with chemotherapy 2 (lorlatinib-with-chemotherapy-2)

Pfizer · FDA-approved active Quality 40/100

Lorlatinib is an investigational therapy being developed by Pfizer for the treatment of non-small cell lung cancer (NSCLC) in combination with chemotherapy. It is a third-generation ALK inhibitor designed to overcome resistance to first and second-generation ALK inhibitors. The drug is currently in clinical trials and has shown promising results in early studies. However, it does not yet have an FDA label, indicating that it is still under review or has not been approved. Common side effects include peripheral neuropathy, hypercholesterolemia, and cognitive effects, among others. The drug's development is part of Pfizer's broader strategy to address unmet needs in NSCLC.

At a glance

Generic namelorlatinib-with-chemotherapy-2
SponsorPfizer
Drug classALK inhibitor
TargetALK
Therapeutic areaOncology
PhaseFDA-approved
Annual revenue798

Approved indications

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: